Despite short-term volatility and reliance on GLP-1 momentum, HIMS remains a long-term bullish play in the consumer digital ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

A Dubai restaurant has introduced a high-protein, smaller-portion menu designed specifically for people using weight-loss injections. Mediterranean restaurant The Banc Dubai says its Mini Bancer menu ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Patients coming off weight loss jabs need support and advice for at least a year to ensure lasting benefit from the drugs, the UK’s medicine watchdog has said. An estimated four in five patients who ...